- 데이터 없음
한국어
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
Recently, a research team from the School of Physics and Optoelectronic Engineering at Jinan University has elucidated for the first time the time-dependent quantum mechanism of two-photon absorption and proposed a two-photon absorption (fpTPA) optical nanoprinting technology based on few photon irradiation, successfully breaking through the bottleneck of traditional two-photon printing technology...
When observing biological samples under a microscope, if the medium in which the objective lens is located is different from the sample, the light beam will be interfered with. For example, when observing a water sample with a lens surrounded by air, the light bends more strongly in the air around the lens than in water.This interference can cause the measured sample depth to be smaller than the a...
Recently, the Fraunhofer Institute (HHI) has developed a technology for processing aluminum alloy materials using reactive gas assisted nanosecond lasers, which can be used to produce electronic box samples for spacecraft manufacturing. This development project is part of the NanoBLAST project, in close collaboration with thermal engineering company Azimut Space GmbH, aimed at manufacturing surfac...
Starting company 3DM from Israel has developed a new laser powder bed fusion technology (SLS) and recently released its first product. It is reported that the new technology developed by this young company established in 2016 will open up the possibility of new materials.3DM quantum cascade laserThe quantum cascade laser (QCL) stands out in the competition of 3DM in the SLS field. QCL was develope...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...